Track topics on Twitter Track topics that are important to you
Sanofi has decided to build its pipeline in neurological disorders with the agreement to develop Principia Biopharma’s BTK inhibitor candidate for multiple sclerosis (MS). The deal works out at $40 million upfront and there is a further $765 million lying in-wait for Principia, dependent upon milestone payments.
Original Article: Sanofi signs $805 million deal for MS drugNEXT ARTICLE
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...